DGAP-News: STADA Arzneimittel AG / Key word(s): Alliance
STADA Arzneimittel AG: STADA strengthens aesthetics area through cooperation
with CROMA-PHARMA and at the same time secures access to Botulinumtoxin A
17.12.2015 / 10:00
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Bad Vilbel, December 17, 2015 - With the goal of expanding its business
activities in the area of dermatological treatments, STADA Arzneimittel AG
will cooperate with the Austrian company CROMA-PHARMA GmbH through its
subsidiary STADA Aesthetics AG in the future.
The long-term cooperation relates to the existing product portfolio as well
as the CROMA-PHARMA product pipeline. Under their premium brand
Princess(R), which is exclusively sold by dermatologists, the company
offers a wide range of products in the area of non-invasive and
minimally-invasive aesthetic dermatology. This includes hyaluronic acid
products in the form of so-called fillers, face masks or serums as well as
innovative medicinal products such as lifting threads. Exclusive brand
licensing rights and other distribution rights for STADA currently relate
to Germany, Belgium, Italy, the United Kingdom, Sweden, Denmark, Finland,
Norway, Hungary, Croatia and Hong Kong. In Germany and Belgium, STADA will
purchase the existing sales companies of CROMA-PHARMA GmbH with a total of
five employees. It is planned that the sale of the products in the German
market will be taken over by the STADA subsidiary STADAvita GmbH, and by
other STADA subsidiaries in the remaining countries.
"The cooperation with CROMA-PHARMA enables us to drive the expansion of the
aesthetic treatment area as planned. Aesthetic medicine has shown
above-average growth potential worldwide which we want to benefit from by
expanding", says Hartmut Retzlaff, Chairman of the Executive Board at STADA
Arzneimittel AG regarding the cooperation's promising perspectives.
Mag. pharm. Andreas Prinz, Managing Director and co-owner of CROMA-PHARMA
GmbH, comments: "We are happy to have found a strong partner for selected
markets in STADA. Both parties will benefit greatly from the cooperation."
CROMA-PHARMA has a well-filled product pipeline. It also includes products
containing the active ingredient Botulinumtoxin A, which is currently in
the clinical study phase 3 for application in cosmetic dermatology.
The purchase price paid by STADA for the existing products and the pipeline
as well as the purchased sales companies is in the single-digit million
euro area. Once an approval of Botulinumtoxin A has been issued, a further
payment in the single-digit million euro range will be due.
CROMA-PHARMA, based in Leobendorf, Austria, was founded in 1976, currently
employs approximately 300 people and has 13 own branch offices. Using sales
organizations/sales partners, the company is active in nearly 100
countries. The aesthetics portfolio of the Princess(R) product line is
developed and manufactured by CROMA-PHARMA. The production is carried out
at the Leobendorf location near Vienna.
About CROMA-PHARMA GmbH:
CROMA-PHARMA is a globally operated family owned pharmaceutical company
based in Leobendorf, Austria. Since 2014 the company has focused its core
business on the booming Anti-Aging market. Based on its expertise
CROMA-PHARMA became one of the most innovative enterprises in the field of
non-invasive and minimally-invasive aesthetic dermatology. Under its
umbrella brand "Princess" CROMA-PHARMA produces and markets skin masks,
serums, intradermal fillers, and lifting threads. The entire product line
is exclusively sold through pharmacies and dermatologists. From early on
CROMA-PHARMA believed in Hyaluronic Acid and with an annual output of
almost 6 million pre-filled syringes CROMA-PHARMA is a leading producer of
Hyaluronic Acid based products. CROMA-PHARMA puts strong efforts in its own
Research & Development which is based at the companies headquarters in
Leobendorf, while also anticipating trends and courageously taking the
opportunities to in-license new products and technologies or acquiring
stakes in other companies. CROMA-PHARMA currently employs approximately 300
people and operates 13 owned subsidiaries. Through a network of
distribution cooperations it's products are available in nearly 100
countries worldwide. CROMA-PHARMA is a National Winner in the European
Business Awards and a committed partner of "Light for the World". This CSR
Partnership has won the company the TRIGOS 2014 award, the most prestigious
award for CSR projects.
About STADA Arzneimittel AG:
STADA Arzneimittel AG is a publicly-listed company with headquarters in Bad
Vilbel, Germany. STADA consistently focuses on a multi-pillar strategy of
generics and branded products (OTC) with an increasingly international
market orientation. The Group is the only independent generics producer in
Germany. Worldwide, STADA is represented in more than 30 countries with
more than 50 subsidiaries. Branded products such as Grippostad and Ladival
are among the highest selling in their product categories in Germany. In
financial year 2014, STADA achieved Group sales of Euro 2,062.2 million,
adjusted earnings before interest, taxes, depreciation and amortization
(EBITDA) of Euro 431.9 million and adjusted net income of Euro 186.2
million. As of December 31, 2014, STADA employed 10,363 people worldwide.
Additional information for analysts:
STADA Arzneimittel AG / Investor Relations / StadastraÃe 2-18 / 61118 Bad
Vilbel - Germany /
Phone: +49 (0) 6101 603-113 / Fax: +49 (0) 6101 603-215 / E-mail:
ir@stada.de
Additional information for journalists:
STADA Arzneimittel AG / Media Relations / StadastraÃe 2-18 / 61118 Bad
Vilbel - Germany /
Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-mail:
press@stada.de
Or visit us in the Internet at www.stada.com.
---------------------------------------------------------------------------
17.12.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: STADA Arzneimittel AG
StadastraÃe 2-18
61118 Bad Vilbel
Germany
Phone: +49 (0)6101 603- 113
Fax: +49 (0)6101 603- 506
E-mail: communications@stada.de
Internet: www.stada.de
ISIN: DE0007251803, DE0007251845,
WKN: 725180, 725184,
Indices: MDAX
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime
Standard); Regulated Unofficial Market in Berlin, Hamburg,
Hanover, Munich, Stuttgart
End of News DGAP News Service
---------------------------------------------------------------------------
424323 17.12.2015
DGAP-News: STADA Arzneimittel AG: STADA strengthens aesthetics area through cooperation with CROMA-PHARMA and at the same time secures access to Botulinumtoxin A
| Source: EQS Group AG